Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) traded down 3.5% during trading on Tuesday . The stock traded as low as $3.06 and last traded at $3.07, with a volume of 79,142 shares trading hands. The stock had previously closed at $3.18.

Several equities research analysts recently commented on the company. Rodman & Renshaw restated a “buy” rating on shares of Kitov Pharmaceuticals Holdings in a research report on Saturday, May 14th. Zacks Investment Research upgraded Kitov Pharmaceuticals Holdings from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research report on Wednesday, April 27th.

The stock’s market cap is $11.98 million. The stock has a 50-day moving average of $3.07 and a 200 day moving average of $3.98.

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.